Glaukos Co. (NYSE:GKOS) Shares Sold by Trust Point Inc.

Trust Point Inc. reduced its stake in shares of Glaukos Co. (NYSE:GKOS) by 42.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,480 shares of the medical instruments supplier’s stock after selling 4,863 shares during the period. Trust Point Inc.’s holdings in Glaukos were worth $972,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Values First Advisors Inc. bought a new stake in Glaukos in the third quarter valued at about $25,000. Harvest Fund Management Co. Ltd increased its holdings in shares of Glaukos by 2,263.2% in the 3rd quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock valued at $117,000 after acquiring an additional 860 shares during the last quarter. KBC Group NV raised its position in shares of Glaukos by 16.2% during the 3rd quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock valued at $188,000 after acquiring an additional 201 shares in the last quarter. Zhang Financial LLC bought a new position in Glaukos during the fourth quarter worth $221,000. Finally, EWA LLC acquired a new position in Glaukos in the third quarter worth $209,000. Institutional investors own 99.04% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on GKOS. Stephens raised shares of Glaukos to a “strong-buy” rating in a report on Monday, December 2nd. StockNews.com raised shares of Glaukos from a “sell” rating to a “hold” rating in a report on Monday, October 21st. Truist Financial lifted their target price on Glaukos from $152.00 to $185.00 and gave the company a “buy” rating in a research note on Wednesday, December 18th. Citigroup raised Glaukos from a “neutral” rating to a “buy” rating and raised their price target for the stock from $132.00 to $162.00 in a report on Wednesday, December 11th. Finally, Morgan Stanley downgraded Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 price objective for the company. in a research note on Monday, December 2nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Glaukos currently has a consensus rating of “Moderate Buy” and an average target price of $151.08.

Glaukos Price Performance

NYSE GKOS opened at $154.50 on Wednesday. Glaukos Co. has a 12 month low of $83.90 and a 12 month high of $163.71. The firm has a market capitalization of $8.52 billion, a PE ratio of -51.16 and a beta of 1.04. The company’s 50 day simple moving average is $149.95 and its 200 day simple moving average is $136.67. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71.

Glaukos (NYSE:GKOS) last posted its quarterly earnings data on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.20. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. The company had revenue of $96.70 million for the quarter, compared to the consensus estimate of $91.50 million. During the same quarter in the previous year, the business earned ($0.50) EPS. The company’s quarterly revenue was up 23.9% compared to the same quarter last year. As a group, equities research analysts forecast that Glaukos Co. will post -1.89 EPS for the current fiscal year.

Insider Buying and Selling at Glaukos

In other Glaukos news, Director Gilbert H. Kliman sold 2,000 shares of Glaukos stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $144.01, for a total transaction of $288,020.00. Following the transaction, the director now owns 32,336 shares of the company’s stock, valued at $4,656,707.36. The trade was a 5.82 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Joseph E. Gilliam sold 3,328 shares of Glaukos stock in a transaction on Friday, December 20th. The shares were sold at an average price of $149.85, for a total transaction of $498,700.80. Following the sale, the chief operating officer now directly owns 102,169 shares of the company’s stock, valued at $15,310,024.65. This trade represents a 3.15 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 15,328 shares of company stock valued at $2,289,521. 6.40% of the stock is owned by insiders.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.